Samsung Biologics

207940.KO

686.49 USD

-2.11

-0.31%

Overview

Last close

686.49 usd

Market cap

31.78B usd

52 week high

761.21 usd

52 week low

600.78 usd

Target price

686.33 usd

Valuation

P/E

N/A

Forward P/E

75.188

Price/Sales

15.7924

Price/Book Value

7.1378

Enterprise Value

59.16B usd

EV/Revenue

15.6582

EV/EBITDA

31.0773

Key financials

Revenue TTM

3.78B usd

Gross Profit TTM

2.11B usd

EBITDA TTM

1.84B usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

13.09B usd

Net debt

205.82M usd

About

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and regulatory support services; and quality, biosafety and analytical testing services, as well as manufactures drug substance. In addition, it engages in the development and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.